Neuphoria Therapeutics Inc. Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost
Neuphoria Therapeutics Inc. (NEUP) had Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost of $1.13 million as of 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost · last filed 2026-09-18
- 2026-06-30: Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost $1.13M.
- 2025-06-30: Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost $1.31M.
- 2024-06-30: Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost $1.49M.
- 2023-06-30: Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost $1.67M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost |
|---|---|
| 2026-06-30 | $1.13M 10-K · filed 2026-09-18 |
| 2025-06-30 | $1.31M 10-K · filed 2026-09-18 |
| 2024-06-30 | $1.49M 10-K · filed 2025-09-29 |
| 2023-06-30 | $1.67M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |